CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes

Publikation: Bidrag til tidsskriftKommentar/debatForskningfagfællebedømt


  • Fulltext

    Forlagets udgivne version, 798 KB, PDF-dokument

  • Oliver Schnell
  • Tadej Battelino
  • Richard Bergenstal
  • Andreas L. Birkenfeld
  • Antonio Ceriello
  • Alice Cheng
  • Melanie Davies
  • Steve Edelman
  • Thomas Forst
  • Francesco Giorgino
  • Jennifer Green
  • Per Henrik Groop
  • Samy Hadjadj
  • Hiddo J.L.Heerspink
  • Marcus Hompesch
  • Baruch Izthak
  • Linong Ji
  • Naresh Kanumilli
  • Boris Mankovsky
  • Chantal Mathieu
  • Martin Miszon
  • Reem Mustafa
  • Michael Nauck
  • Roberto Pecoits-Filho
  • Jeremy Pettus
  • Kari Ranta
  • Helena W. Rodbard
  • Lars Ryden
  • Petra Maria Schumm-Draeger
  • Scott D. Solomon
  • Jan Škrha
  • Pinar Topsever
  • John Wilding
  • Eberhard Standl

The 8th Cardiovascular Outcome Trial (CVOT) Summit on Cardiovascular, Kidney, and Glycemic Outcomes was held virtually on November 10–12, 2022. Following the tradition of previous summits, this reference congress served as a platform for in-depth discussion and exchange on recently completed outcomes trials as well as key trials important to the cardiovascular (CV) field. This year’s focus was on the results of the DELIVER, EMPA-KIDNEY and SURMOUNT-1 trials and their implications for the treatment of heart failure (HF) and chronic kidney disease (CKD) with sodium-glucose cotransporter-2 (SGLT2) inhibitors and obesity with glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonists. A broad audience of primary care physicians, diabetologists, endocrinologists, cardiologists, and nephrologists participated online in discussions on new consensus recommendations and guideline updates on type 2 diabetes (T2D) and CKD management, overcoming clinical inertia, glycemic markers, continuous glucose monitoring (CGM), novel insulin preparations, combination therapy, and reclassification of T2D. The impact of cardiovascular outcomes on the design of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) trials, as well as the impact of real-world evidence (RWE) studies on the confirmation of CVOT outcomes and clinical trial design, were also intensively discussed. The 9th Cardiovascular Outcome Trial Summit will be held virtually on November 23–24, 2023 (

TidsskriftCardiovascular Diabetology
Udgave nummer1
StatusUdgivet - 2023

Bibliografisk note

Funding Information:
We would like to thank all speakers and participants of the 8th CVOT Summit for their active involvement in the scientific discussions leading to the present report. We also like to thank Dr. Sofia Macieira, Sciarc GmbH, for her writing and editorial support of the manuscript. Moreover, we want to acknowledge our industry partners for their support of the summit.

Publisher Copyright:
© 2023, The Author(s).

ID: 344645953